Slingshot members are tracking this event:

Moleculin Biotech (MBRX) receives approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Aml, Acute Myeloid Leukemia, Annamycin